Unlocking mRNA Vaccine, Therapeutics & Platform Technologies from Discovery to Commercialization With Targeted Extrahepatic Delivery, Dose Longevity & Improved Safety for Oncology, Rare & Infectious Diseases & Beyond
The mRNA field was on the cusp of revolutionary change, with cancer vaccines, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidates and developmental progress towards clinical and commercial approval.
To shine light on emerging areas and the latest progress, the 5th mRNA-Based Therapeutics Summit returned to Boston in 2025, as the world's largest, end-to-end mRNA conference, gathering 320+ global stakeholders, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA, Circular RNA & Self-Amplifying RNA fields including Moderna, Pfizer, BioNTech, Grann Pharmaceuticals, Celestial Therapeutics, Byterna Therapeutics and more.
Attendees discovered the realms of new infectious disease platforms, combating oncological targets and cell therapies across 4 dedicated tracks of content in Discovery, Pre-Clinical Development, Clinical Development and, Manufacturing & CMC. This was their one-stop-shop for scientific content and partnering to aid the progress of pipelines in 2025 towards the clinic and ultimately patients in need.
The Summit is an engaging platform to gain insights into the latest advancements and shape industry best practices to drive the progress of mRNA therapeutics.
Shyam Kumar Gudey, Principal Scientist, Moderna
This is one of the key mRNA meetings in the industry, covering up and coming scientific advances in the field as well as providing parallel sessions on clinical candidates and access to key opinion leaders as well as the regulators for this field.
George Thom, Director & mRNA Team Leader, AstraZeneca
Participating in the Summit reinforces our leadership in advancing sa-mRNA innovations, fosters impactful collaborations, and shapes the future of RNA-based solutions for global health challenges.
Lingtao Peng, Director & Head of Molecular, Cellular & Synthetic Biology, CSL
Snapshot of 2025 Speakers:
Official Partners
Expertise Partners
Attending Companies Included
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights on the mRNA innovations during our packed agenda, interactive roundtables, and new CEOs & investor panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of mRNA biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.